AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and ...
ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.
In Q3, the top 10 TV ad spenders poured a combined $544.8 million into airing their commercials, according to data shared ...
AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a ...
MarketBeat on MSN
3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years
For many investors, getting involved with pharmaceutical stocks involves finding inexpensive stocks, often penny stocks, in ...
Discover Merck & Co., Inc.'s Q3 earnings outlook as Keytruda's patent nears expiry. Click for my updated look at MRK stock ...
The use of interleukin (IL)-23 inhibitors plays an important role in treating patients with psoriasis, as well as in treating ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. North Chicago-based AbbVie, one of the nation's largest ...
This second round of layoffs marks more than 300 employees let go within the year. Despite the cuts, health insurers are ...
Oct 30 (Reuters) - Drugmaker AbbVie Inc (ABBV.N), opens new tab raised its full-year profit forecast on Friday, bolstered by signs of recovery in demand for its Botox injection on easing COVID-19 ...
(Reuters) -AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback